| Zhang, Hong |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
TaLaR-02, NCT05984485: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 766 | RoW | neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision | Sun Yat-sen University | Rectal Cancer | 07/28 | 07/28 | | |
NCT05702489: A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza |
|
|
| Completed | 2/3 | 900 | RoW | ZX-7101A | Nanjing Zenshine Pharmaceuticals | Influenza, Human | 05/23 | 10/23 | | |
NCT04398459: The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia |
|
|
| Active, not recruiting | 2 | 18 | RoW | Ibrutinib, BTK inhibitor | Institute of Hematology & Blood Diseases Hospital, China | Refractory/Relapsed Autoimmune Hemolytic Anemia | 12/24 | 06/25 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT06670352: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN |
|
|
| Recruiting | 2 | 80 | RoW | Placebo, HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD | Haisco Pharmaceutical Group Co., Ltd. | IgA Nephropathy (IgAN) | 11/25 | 03/26 | | |
BID-PERAL, NCT04423367: Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment |
|
|
| Completed | 2 | 18 | RoW | bortezomib/dexamethasone | Institute of Hematology & Blood Diseases Hospital, China | Acquired Pure Red Cell Aplasia | 07/24 | 09/24 | | |
NCT05660785: Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia |
|
|
| Active, not recruiting | 2 | 54 | RoW | Herombopag, Cyclosporine A | Institute of Hematology & Blood Diseases Hospital, China, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Non Severe Aplastic Anemia, Untreated | 01/25 | 05/25 | | |
NCT06687174: Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 72 | RoW | MY008211A tablets, MY008211A tablets matched placebo | Wuhan Createrna Science and Technology Co., Ltd | IgA Nephropathy (IgAN) | 06/26 | 01/28 | | |
NCT06760182: Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQH2722 injection, TQH2722 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Seasonal Allergic Rhinitis | 06/25 | 08/25 | | |
NCT04688736: Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. |
|
|
| Recruiting | 2 | 6642 | RoW | Placebo, Chlorpheniramine | Institute of Hematology & Blood Diseases Hospital, China | Allergic Transfusion Reaction | 12/25 | 06/26 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT04481841: Head Yuanshi Dian Therapy in Burning Mouth Syndrome |
|
|
| Recruiting | 1 | 290 | RoW | oryzanol + vitamin B2 (riboflavin) + vitamin E, head yuanshi dian therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology | Burning Mouth Syndrome, Oral Mucosa Disease | 02/22 | 05/22 | | |
NCT06101316: A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China |
|
|
| Recruiting | 1 | 12 | RoW | CB06-036 | Shanghai Zhimeng Biopharma, Inc. | Healthy Volunteers | 10/23 | 12/23 | | |
NCT06216041: To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects |
|
|
| Recruiting | 1 | 138 | RoW | IMM-H014, Placebo, IMM-H014 ( FE), Placebo ( FE) | Changchun Intellicrown Pharmaceutical Co. LTD | Nonalcoholic Steatohepatitis (NASH) | 07/24 | 12/24 | | |
NCT06160895: A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects |
|
|
| Completed | 1 | 40 | RoW | TQ-A3334 tablets, TQ-A3334 placebo tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B | 06/24 | 08/24 | | |
NCT06427681: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 40 | NA | BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection, EMEND®+PALONOSETRON | Zhuhai Beihai Biotech Co., Ltd | Bioavailability | 09/24 | 12/24 | | |
| Not yet recruiting | 1 | 18 | NA | AP303 150μg, AP303 300μg, Placebo 150μg, Placebo 300μg | Alebund Pharmaceuticals | Diabetic Kidney Disease | 01/25 | 01/25 | | |
| Completed | N/A | 980 | RoW | Rotational Atherectomy | Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd. | Coronary Artery Disease | 12/20 | 01/22 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
NCT05608980: 0.01% Hypochlorous Acid in the Treatment of Blepharitis |
|
|
| Recruiting | N/A | 100 | RoW | 0.01% hypochlorous acid, 0.01%HOCI, Placebo | Eye & ENT Hospital of Fudan University, ShuGuang Hospital | Blepharitis | 12/22 | 05/23 | | |
NCT05685966: Retrospective Study of COVID-19 on Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 | 03/23 | 01/24 | | |
NCT04852406: Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy |
|
|
| Recruiting | N/A | 526 | RoW | Protocol-based management of perioperative antithrombotic therapy, Protocol-based management, Routine management of perioperative antithrombotic therapy, Routine management | Peking University First Hospital | Antithrombotic Therapy, Perioperative Care, Perioperative Outcomes | 12/23 | 01/24 | | |
NCT05685992: Novel Coronavirus Infection and Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 Infection | 01/24 | 01/24 | | |
CSILS, NCT04527861: Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 710 | RoW | Single-incision Laparoscopic Surgery, SILS, Conventional Laparoscopic Surgery, CLS | Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Fudan University, Changhai Hospital, Shengjing Hospital, RenJi Hospital, Liaoning Cancer Hospital & Institute, Zhejiang Provincial People's Hospital, Shandong Provincial Hospital, The General Hospital of Western Theater Command, Shanghai Jiao Tong University School of Medicine | Colorectal Cancer, Colon Cancer, Rectal Cancer | 04/24 | 04/29 | | |
NCT04645810: A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence |
|
|
| Recruiting | N/A | 12 | US | High-Dose-Rate Brachytherapy | University of Rochester | Prostate Cancer, HDR | 05/26 | 05/27 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Recruiting | N/A | 1114 | RoW | TaTME, Transanal TME, LpTME, Laparoscopic TME | Sun Yat-sen University, Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University | Rectal Neoplasms Malignant, Surgery | 07/26 | 07/26 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Not yet recruiting | N/A | 550 | RoW | lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Colorectal Neoplasms, Fluorescence, Lymph Node Excision | 12/26 | 06/27 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Shi, Jing Ming |
NCT04780399: Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease |
|
|
| Recruiting | 2 | 216 | RoW | Yangxue Qingnao pills, Placebo | Dongzhimen Hospital, Beijing | Alzheimer Disease, Yangxue Qingnao Pills, Randomized | 03/24 | 12/24 | | |
NCT05371639: Efficacy and Safety of Tian Ma Bian Chun Zhi Gan Tablets in Mild to Moderate Vascular Dementia |
|
|
| Recruiting | 2 | 360 | RoW | Tian Ma Bian Chun Zhi Gan Tablets, Placebo | Dongzhimen Hospital, Beijing | Vascular Dementia, Cognitive Impairment | 12/24 | 06/25 | | |
NCT06225713: Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD) |
|
|
| Recruiting | N/A | 80 | RoW | focused power ultrasound mediated inferior perirenal adipose tissue modification, sham-control group | The First Affiliated Hospital with Nanjing Medical University, The Affiliated Jiangning Hospital of Nanjing Medical University, Suzhou Municipal Hospital | Non-alcoholic Fatty Liver Disease | 10/24 | 12/24 | | |
NCT05850923: The Efficacy of Speech Competition Training on Auditory Hallucination in Schizophrenia |
|
|
| Recruiting | N/A | 100 | RoW | speech competition training, the soothing music | Jing SHI | Auditory Hallucination | 06/24 | 06/24 | | |
| Xu, Wei |
NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression |
|
|
| Recruiting | 3 | 606 | RoW | Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops | Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc. | Myopia, Myopia Progression | 12/26 | 12/27 | | |
NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL |
|
|
| Recruiting | 3 | 104 | RoW | C-BEAM Regimen, BEAM Regimen | The First Affiliated Hospital with Nanjing Medical University | Newly Diagnosed Peripheral T-cell Lymphoma | 02/26 | 02/28 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT04423926: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL |
|
|
| Recruiting | 2 | 91 | RoW | Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone | The First Affiliated Hospital with Nanjing Medical University | PTCL, NOS, AITL, ALK- ALCL, Phase III-IV ALK+ ALCL, EATL | 12/22 | 12/24 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05241132: Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary |
|
|
| Recruiting | 2 | 27 | RoW | Tislelizumab plus chemotherapy, Cisplatin, Paclitaxel | Wei Xu | Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer, Immune Evasion, Tumor, Chemotherapy Effect | 06/23 | 10/24 | | |
NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS |
|
|
| Recruiting | 2 | 55 | RoW | Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone | The First Affiliated Hospital with Nanjing Medical University | EBV-Positive DLBCL, Nos | 12/23 | 12/23 | | |
NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 54 | RoW | penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin | The First Affiliated Hospital with Nanjing Medical University | Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type | 01/24 | 02/26 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT06594432: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement |
|
|
| Not yet recruiting | 2 | 40 | RoW | R-CHOP+Z+MTX, R-CHOP+MTX | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B Cell Lymphoma (DLBCL) | 12/26 | 06/27 | | |
NCT04432714: Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement |
|
|
| Recruiting | 2 | 81 | RoW | Lenalidomide, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone | The First Affiliated Hospital with Nanjing Medical University | DLBCL, Untreated, MYC Gene Rearrangement | 12/24 | 12/26 | | |
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Terminated | 1/2 | 23 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 11/23 | 11/23 | | |
NCT05323201: Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer |
|
|
| Recruiting | 1/2 | 15 | RoW | fhB7H3.CAR-Ts, B7H3 targeting chimeric antigen receptor T cells, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan | The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, IIT MediTech Co. Ltd | Hepatocellular Carcinoma | 02/24 | 02/27 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies |
|
|
| Recruiting | 1 | 37 | RoW | TT-01488 Tablets | TransThera Sciences (Nanjing), Inc. | B-Cell Malignancies | 10/26 | 10/28 | | |
NCT05173467: Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor |
|
|
| Not yet recruiting | N/A | 60 | RoW | Robot-assisted Invasion-controlled Surgery, Traditional-open Surgery | Wei Xu | Minimally Invasive Surgery, Spinal Metastases | 12/22 | 12/23 | | |
NCT04432402: Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | N/A | 124 | RoW | Lenalidomide, Rituximab, Gemcitabine, oxaliplatin | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B Cell Lymphoma | 12/22 | 12/24 | | |
| Recruiting | N/A | 286 | RoW | Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation | Ruijin Hospital | Atrial Fibrillation, Persistent, Arrhythmias, Cardiac | 07/25 | 01/26 | | |
NCT05777369: R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | N/A | 30 | NA | Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 08/23 | 08/24 | | |
| Recruiting | N/A | 50 | RoW | Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome | The First Affiliated Hospital with Nanjing Medical University | Relapsed/Refractory Peripheral T-cell Lymphoma | 09/25 | 09/25 | | |
| Not yet recruiting | N/A | 60 | NA | Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 01/24 | 01/25 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
NCT05426824: The Whole-course Management of Pegaspargase in ENKTL |
|
|
| Not yet recruiting | N/A | 72 | RoW | Pegaspargase（P-GOD）, Pegaspargase（PEMD） | The First Affiliated Hospital with Nanjing Medical University | Extranodal NK/T Cell Lymphoma | 07/24 | 07/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05896813: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
|
|
| Recruiting | N/A | 30 | RoW | CMOP+Chidamide | The First Affiliated Hospital with Nanjing Medical University | Newly Diagnosed Peripheral T-cell Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | N/A | 399 | Europe, US | Shockwave Medical Coronary IVL System | Shockwave Medical, Inc. | Coronary Artery Disease | 12/24 | 04/28 | | |
NCT05343377: A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma |
|
|
| Not yet recruiting | N/A | 72 | RoW | circulate free methylated EBV DNA | The First Affiliated Hospital with Nanjing Medical University, Zhenjiang First People's Hospital, Changzhou First People's Hospital, Changzhou Second People's Hospital, Wuxi People's Hospital, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nantong University, Huaian first people's hospital, Yancheng First People's Hospital | Extranodal Natural Killer/T-cell Lymphoma | 06/25 | 06/28 | | |
NCT06120426: En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor. |
|
|
| Recruiting | N/A | 182 | RoW | total en bloc spondylectomy | Shanghai Changzheng Hospital, Peking University Third Hospital, Peking University People's Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Zhejiang University, Tianjin Hospital, The First Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Southern Medical University | Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor, Surgery | 07/25 | 07/27 | | |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
NCT05967949: A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. |
|
|
| Recruiting | N/A | 200 | RoW | chidamide | The First Affiliated Hospital with Nanjing Medical University | PTCL | 04/26 | 04/28 | | |
NCT05645302: Intensive Monitoring Scheme of Lidocaine Cataplasms |
|
|
| Recruiting | N/A | 200 | RoW | Lidocaine Cataplasms | Qianfoshan Hospital | Adverse Reaction to Drug | 10/22 | 12/22 | | |
| Lin, Chang |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 05/25 | 05/26 | | |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
NCT05901480: An Investigator Initiated Study for OTOV101N+OTOV101C Injection |
|
|
| Recruiting | N/A | 25 | RoW | OTOV101N+OTOV101C Injections | Otovia Therapeutics | DFNB9 | 12/24 | 02/25 | | |
| zhu, anlong |
NCT05352074: STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation |
|
|
| Recruiting | N/A | 202 | RoW | subtotal colectomy with cecal-rectal anastomosis, total colectomy with ileorectal anastomosis | Third Military Medical University | Slow Transit Constipation, Surgery | 12/24 | 12/26 | | |
| Li, Yue |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
| Not yet recruiting | 3 | 8862 | RoW | Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo | Wuhan Union Hospital, China | Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine | 03/28 | 08/28 | | |
NCT04222530: The Diagnosis of Invasive Depth of Early Rectal Cancer |
|
|
| Not yet recruiting | N/A | 81 | NA | Linear EUS first, ME-NBI first | Nanfang Hospital of Southern Medical University | Early Rectal Cancer | 06/22 | 12/22 | | |
| Recruiting | N/A | 100 | RoW | Dopamine, Fractional Flow Reserve, Renal, Renal artery stenting | Peking University First Hospital | Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial | 03/25 | 03/25 | | |
NCT06394089: Effect of Degenerative Spondylolisthesis on the Clinical Outcome of Unilateral Biportal Endoscopy for Lumbar Spinal Stenosis: Study Protocol |
|
|
| Recruiting | N/A | 240 | RoW | | Beijing Friendship Hospital | Degenerative Spondylolisthesis, Lumbar Spinal Stenosis | 02/27 | 02/27 | | |
NCT06357026: Phitys I™ Percutaneous Left Ventricular Assist System Study |
|
|
| Not yet recruiting | N/A | 344 | RoW | Percutaneous Ventricular Assist System（Phigine Medical）, intra-aortic balloon pump (IABP) | Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd. | Coronary Artery Disease | 05/25 | 04/26 | | |
NCT04493086: Effect of FFRCT-angio in Functional Diagnosis of Coronary Artery Stenosis |
|
|
| Recruiting | N/A | 500 | RoW | FFRCT-angio | First Affiliated Hospital of Harbin Medical University | Coronary Artery Disease | 10/21 | 12/21 | | |
NCT05191342: Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 75 | RoW | Enzyme-linked immunosorbent assay for PCSK9 | First Affiliated Hospital of Harbin Medical University | PCSK9 | 11/22 | 11/22 | | |
| Liu |
NCT06755151: Fenofibrate in Primary Biliary Cholangitis: a Real World Study |
|
|
| Recruiting | 3 | 300 | RoW | Fenofibrate | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis (PBC) | 12/35 | 12/35 | | |
NCT06755541: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study |
|
|
| Recruiting | 3 | 150 | RoW | Fenofibrate in Combination With Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis (PBC) | 12/35 | 12/35 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
| Recruiting | 1 | 230 | US, RoW | DZD8586 | Dizal Pharmaceuticals | Lymphoma, Non-Hodgkin | 04/27 | 10/27 | | |
| Sun, Bei |
NCT05774873: IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 128 | RoW | IBI334 D, IBI334 C, IBI334 A, IBI334 B, IBI334 F, IBI334 E | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumors | 10/25 | 06/26 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
| Zhang, Zhiyi |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Zhao, Lei |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT06296563: Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC |
|
|
| Recruiting | 2 | 20 | RoW | HAIC, Adebrelimab, Apatinib | Lei ZHAO | Intrahepatic Cholangiocarcinoma | 03/27 | 03/29 | | |
RICE, NCT06510660: Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC |
|
|
| Recruiting | 2 | 48 | RoW | adebrelimab | Fujian Medical University Union Hospital, Sun Yat-sen University | Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers | 12/25 | 12/28 | | |
MA-HCC-II-015, NCT05099848: A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 21 | RoW | Camrelizumab, Apatinib, FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets | Shandong Cancer Hospital and Institute, Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 06/24 | 12/24 | | |
| Active, not recruiting | 1 | 20 | RoW | PD-1 plus stereotactic body radiotherapy | Shandong Cancer Hospital and Institute, BeiGene | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
